NCT00410306View on ClinicalTrials.gov

Use of Nebido® to Assess Tolerability and Treatment Outcomes in Daily Clinical Practice

CompletedOBSERVATIONAL
Enrollment

1,493

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions
MaleHypogonadism
Interventions
DRUG

Testosterone Undecanoate (Nebido, BAY86-5037)

Patients from routine practice

Trial Locations (33)

Unknown

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY